“With a pandemic like this, the upside for us is clearly significant,’’ said Andrin Oswald, chief executive of Cambridge-based Novartis Vaccines and Diagnostics, a unit of the Swiss pharmaceutical giant. “The quicker we can ramp up our volume, the better it will be for people in the United States and around the world.’’Novartis and four other drug makers - Sanofi-aventis, GlaxoSmithKline, CSL Limited, and MedImmune - heeded the call to action by health officials when swine flu was identified last spring.
They quickly accelerated production of seasonal flu vaccine to free up capacity to make H1N1 vaccine, revamping their distribution systems and wrestling with low “yields’’ of inactivated virus strains in their egg-based swine flu vaccine production system. Shipments began last month and are expected to continue into next year.
Boston.com
Sem comentários:
Enviar um comentário